Evidence map›Paper›PMID 22373584›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012

The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro.

Chunfang Hao, Sen Wei, Zhongsheng Tong, Shufen Li, Yehui Shi, Xiaorui Wang, Zhi-hua Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. PEBP1 inhibition as a therapeutic target for neurological recovery in ischemic stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Pan-Cancer Computational Analysis of RKIP (International journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. The biological complexity of RKIP signaling in human cancers.Experimental & molecular medicine · 2015
    Review
  9. Expression of RKIP in chronic myelogenous leukemia K562 cell and inhibits cell proliferation by regulating the ERK/MAPK pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  10. Article
  11. Low RKIP expression associates with poor prognosis in bladder cancer patients.Virchows Archiv : an international journal of pathology · 2013
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chunfang HaoDepartment of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300060, China.
Sen Wei
Zhongsheng Tong
Shufen Li
Yehui Shi
Xiaorui Wang
Zhi-hua Zhu
Tianjin Medical University Cancer Institute and Hospital · CNSun Yat-sen University Cancer Center · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to investigate the effect of Raf kinase inhibitor protein (RKIP) on the growth, proliferation, invasion and metastasis of triple-negative breast cancer (TNBC) cells to provide experimental evidence for developing future therapies against human TNBC. The pcDNA3.1-RKIP eukaryotic expression vector was constructed and transfected into the TNBC cell line MDA-MB-231. The alterations of the biological characteristics of RKIP-transfected MDA-MB-231 cells were analyzed using the following approaches: a growth curve, a 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assay, bromodeoxyuridine (BrdU) staining and a cell migration assay. The effects of the RKIP gene on MMP-1 and MMP-2 expression were also examined. The pcDNA3.1 empty vector-transfected and mock-transfected MDA-MB-231 cells were used as control groups. Compared with the empty vector-transfected and mock-transfected cells, the cell growth of RKIP-transfected MDA-MB-231 cells was significantly reduced. The empty vector-transfected group was not significantly different compared with the mock-transfected MDA-MB-231 cells. The results of the MTT and BrdU assays demonstrated that the proliferation of pcDNA3.1-RKIP-transfected cells was significantly reduced compared to the control cells (P < 0.05). The result of the cell migration assay suggested that the cross-membrane migration rate of the pcDNA3.1-RKIP-transfected cells was significantly lower than that of the control MDA-MB-231 cells (P < 0.05). We also demonstrated that RKIP may inhibit MMP-1 and MMP-2 expression in MDA-MB-231 cells. The RKIP gene may play a role in inhibiting cellular proliferation. The RKIP gene may also have some inhibitory effects on the invasiveness and metastatic capability of human TNBC cells.

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticBlotting, WesternBreast NeoplasmsCell Line, TumorCell MovementCell SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMatrix Metalloproteinase 1Matrix Metalloproteinase 2Phosphatidylethanolamine Binding ProteinReceptors, EstrogenReceptors, ProgesteroneReverse Transcriptase Polymerase Chain ReactionErb-b2 Receptor Tyrosine KinasesMatrix Metalloproteinase 1Matrix Metalloproteinase 2PEBP1 protein, humanPhosphatidylethanolamine Binding ProteinReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID22373584
OpenAlexW2001974681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.